Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRA-HF
2024-511502-24-02Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF), hyperkalemia and heart failure (HF) comparing SZC arm with Placebo arm (2 arms). Started Aug 2024; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)hyperkalemiaheart failure (HF)
Beyond the preview
Go deeper on 2024-511502-24-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511502-24-02.